Oncology Institute (TOIIW) Common Equity (2019 - 2026)

Oncology Institute (TOIIW) has 8 years of Common Equity data on file, last reported at -$16.3 million in Q1 2026.

• For the quarter ending Q1 2026, Common Equity fell 421.27% year-over-year to -$16.3 million; the trailing twelve-month figure through Mar 2026 stood at -$16.3 million (down 421.27% YoY), and the FY2025 full-year result was -$15.7 million, down 538.01% from the prior year.
• Common Equity for Q1 2026 stood at -$16.3 million, down from -$15.7 million in the prior quarter.
• Across five years, Common Equity topped out at $132.0 million in Q1 2022 and bottomed at -$16.3 million in Q1 2026.
• The 5-year median for Common Equity is $41.3 million (2024), against an average of $50.6 million.
• The widest annual swing landed in 2022, when Common Equity soared 179.98%; it then tumbled 538.01% in 2025.
• A 5-year view of Common Equity shows it stood at $123.2 million in 2022, then tumbled by 53.7% to $57.0 million in 2023, then plunged by 93.71% to $3.6 million in 2024, then sank by 538.01% to -$15.7 million in 2025, then retreated by 3.59% to -$16.3 million in 2026.
• The last three Common Equity figures came in at -$16.3 million (Q1 2026), -$15.7 million (Q4 2025), and -$12.3 million (Q3 2025), per Business Quant data.

Peer Comparison